Limited Edition Golden Llama is here! Check out how you can get one.
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!
Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers !
Shipping Price Reduction for EU Regions
Kat. Nr. | Arten | Produktbeschreibung | Struktur | Reinheit | Merkmal |
---|---|---|---|---|---|
GMP-TG1H25 | Human | GMP Human TGF-Beta 1 / TGFB1 Protein | ![]() |
![]() ![]() |
|
TG1-H5218 | Human | Human TGF-Beta 1 / TGFB1 Protein, premium grade | ![]() |
![]() ![]() |
|
TG1-M8218 | Mouse / Rat | Biotinylated Mouse / Rat TGF-Beta 1 / TGFB1 Protein, Avitag™ | ![]() |
||
TG1-M5218 | Mouse / Rat | Mouse / Rat TGF-Beta 1 / TGFB1 Protein, Tag Free | ![]() |
![]() ![]() |
|
TG1-H8217 | Human | Biotinylated Human TGF-Beta 1 / TGFB1 Protein, Avitag™ | ![]() |
![]() ![]() |
|
TG1-H4212 | Human | Human TGF-Beta 1 / TGFB1 Protein, Tag Free | ![]() |
![]() ![]() |
GMP Human TGF-Beta 1 Protein (Cat. No. GMP-TG1H25) inhibits the GMP Human IL-4 Protein (Cat. No. GMP-L04H26) dependent proliferation the TF-1 cells. The specific activity of GMP Human TGF-Beta 1 Protein is > 6.00ⅹ10^6 IU/mg, which is calibrated against transforming growth factor β1 (NIBSC code:89/514) (QC tested).
Human TGF-beta 1, premium grade (Cat. No. TG1-H5218) inhibits the Human IL-4, premium grade (Cat. No. IL4-H4218) dependent proliferation the TF-1 cells. The specific activity of Human TGF-beta 1, premium grade is > 6.00ⅹ10^6 IU/mg, which is calibrated against transforming growth factor β1 (NIBSC code:89/514) (QC tested).
Human TGF-Beta 1 Protein, Tag Free (Cat. No. TG1-H4212) immobilized on CM5 Chip can bind Human TGF-beta RI Protein, Fc Tag (Cat. No. TG1-H5254) with an affinity constant of 99.2 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Vactosertib | TEW-7197; EW-7197; NOV-1301 | Phase 3 Clinical | Medpacto Inc | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Myelodysplastic Syndromes; Carcinoma, Transitional Cell; Myeloproliferative Disorders; Osteosarcoma; Colorectal Neoplasms; Urologic Neoplasms; Esophageal adenocarcinoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
Bintrafusp alfa | M-7824; GSK-4045154; MSB-0011359C | Phase 3 Clinical | Merck Serono | Lung Neoplasms; Sarcoma; Cholangiocarcinoma; Breast Neoplasms; Microsatellite Instability; Vulvar Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Colorectal Neoplasms; Oropharyngeal Neoplasms; Thymus Neoplasms; Gallbladder Neoplasms; Adenomyoepithelioma; Lymphoma; Brain metastases; Urogenital Neoplasms; Thymoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Sarcoma, Kaposi; Triple Negative Breast Neoplasms; Solid tumours; Hematologic Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Anus Neoplasms; Stomach Neoplasms; Carcinoma; Carcinoma, Renal Cell; Esthesioneuroblastoma, Olfactory; Biliary Tract Neoplasms; Neoplasms; Colonic Neoplasms; Small Cell Lung Carcinoma; Papillomavirus Infections; Carcinoma, Transitional Cell; Nose Neoplasms; Ganglioglioma; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms | Details |
Nisevokitug | NIS-793 | Phase 3 Clinical | Xoma Corp | Kidney Neoplasms; Liver Neoplasms; Pancreatic Neoplasms; Myelodysplastic Syndromes; Small Cell Lung Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Primary Myelofibrosis; Carcinoma, Pancreatic Ductal; Lung Neoplasms; Adenocarcinoma | Details |
SB-01 (Spine Biopharma) | SB-01 | Phase 3 Clinical | Spine BioPharma Inc | Intervertebral disc disease; Low Back Pain | Details |
Dalutrafusp alfa | GS-1423; AGEN-1423 | Phase 2 Clinical | Agenus Inc | Liver Neoplasms; Solid tumours; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal | Details |
ZSP-1603 | ZSP-1603 | Phase 2 Clinical | Wuxi Apptec Co Ltd, Guangdong Zhongsheng Pharmaceutical Co Ltd | Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Colonic Neoplasms; Idiopathic Pulmonary Fibrosis; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Nicousamide | XLF-III-43 | Phase 2 Clinical | Institue Of Materia Medica Chinese Academy Of Medical Science | Hypertensive nephropathy; Diabetic Nephropathies | Details |
Meflonidone hydrochloride | Phase 2 Clinical | Guangzhou Nanxin Pharma Co Ltd, Central South University | Diabetes Mellitus, Type 2; Diabetic Nephropathies | Details | |
Fluorofenidone | AKF-PD | Phase 2 Clinical | Dierepharma HK Ltd, Hainan Haiyao Co Ltd, Central South University | Liver Cirrhosis | Details |
Cotsiranib | STP-705LU; STP-705LV; STP-705; STP-705L | Phase 2 Clinical | Sirnaomics, Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd | Liver Neoplasms; Carcinoma, Basal Cell; Carcinoma, Basosquamous; Cholangiocarcinoma; Obesity, Abdominal; Keloid; Cicatrix, Hypertrophic; Carcinoma, Hepatocellular | Details |
Yinfenidone Hydrochloride | HEC-585; HEC-00000585 | Phase 2 Clinical | Hec Pharm Co Ltd | Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial | Details |
YL-13027 | YL-13027 | Phase 2 Clinical | YL-Pharma | Solid tumours; Pancreatic Neoplasms | Details |
Linavonkibart | SRK-181 | Phase 1 Clinical | Scholar Rock | Neoplasms | Details |
Charis-1000 | Charis-1000; C 1K; C1K | Phase 1 Clinical | Breast Neoplasms | Details | |
HLX-6018 | HLX-6018; HLX6018 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Idiopathic Pulmonary Fibrosis | Details |
JYB-1907 | JYB-1907 | Phase 1 Clinical | Jiangxi Jemincare Group Co Ltd | Solid tumours | Details |
STP-707 | STP-707 | Phase 1 Clinical | Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd | Solid tumours; Liver Neoplasms; Liver Cirrhosis; Pulmonary Fibrosis; Cholangitis, Sclerosing | Details |
PXS-64 | PXS-64 | Phase 1 Clinical | Multiple Sclerosis | Details | |
Livmoniplimab | MGH-8; ARGX-115; AGRX-115; ABBV151 | Phase 1 Clinical | Argenx Se | Carcinoma, Hepatocellular | Details |
AVID-200 | AVID-200; BMS-986416; AVID-200 DP | Phase 1 Clinical | Formation Biologics Corp | Solid tumours; Polycythemia Vera; Primary Myelofibrosis; Scleroderma, Diffuse; Thrombocythemia, Essential | Details |
This web search service is supported by Google Inc.